Login / Signup

Outcomes and Characteristics of Non-Melanoma Skin Cancers in Patients with Myeloproliferative Neoplasms on Ruxolitinib.

Alexandros RampotasLuke Carter-BrzezinskiTim C SomervailleJames ForryanFotios P PanitsasClaire N HarrisonRuth WitherallAndrew J InnesLouise WallisNauman M ButtBethan PsailaAdam J MeadMatthew CarterAnna L GodfreyHeather LaingMamta GargSebastian FrancisJoanne EwingChun Huat TehHannah B CowanPeter DyerConal McConvilleFrances WadelinSahra AliAndrew McGregorElizabeth KulakovDonal P McLornanJonathan Lambert
Published in: Blood (2023)
Non-melanoma skin cancers in ruxolitinib-treated MPN patients behave aggressively, with adverse features and high recurrence. In our cohort, mortality from metastatic NMSC exceeded that from myelofibrosis . Vigilant skin assessment, counselling on NMSC risks, and prospective ruxolitinib-NMSC studies are crucial.
Keyphrases